The International Society for Stem Cell Research has issued a statement that “When a professional consensus on the safety and therapeutic value of a treatment is lacking, the ISSCR believes it is unethical and unprofessional to market such interventions directly to patients”. The COA supports this statement.
JointPlan News
By JointPlan
OrthoLink is the Foundation’s newsletter, written for people interested in building and keeping their bone and joint health.